MINI REVIEW article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1636332
Anti-angiogenesis in human lymphomas. New insights
Provisionally accepted
- University of Bari Aldo Moro, Bari, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract. Targeting tumor angiogenesis is an advancement in the treatment of hematological malignancies. This article summarizes the most recent advancements in the use of anti-angiogenic agents in the treatment of human lymphomas. Preclinical and clinical studies have evidenced that that treating lymphomas with anti-angiogenic monotherapy may not be successful. Alternative therapeutic strategies may be used to overcome resistance to anti-angiogenic therapy, including the association of different anti-angiogenic molecules or their combination with other treatment regimens.
Keywords: Angiogenesis, anti-angiogenesis, Hodgkin lymphomas, Non-Hodgkin lymphomas, tumor progression
Received: 27 May 2025; Accepted: 24 Sep 2025.
Copyright: © 2025 RIBATTI, Tamma, Ingravallo and Specchia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Domenico RIBATTI, domenico.ribatti@uniba.it
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.